Cohera Medical, Inc. Expands Management Team

    PITTSBURGH, Jan. 7 /PRNewswire/ -- Cohera Medical, Inc., a rapidly
 growing medical device company developing a suite of wound management
 systems and surgical adhesives, announced today that it has expanded its
 executive management team with the appointment of Chad Coberly as Vice
 President of Clinical, Regulatory and Legal Affairs. Mr. Coberly has more
 than 15 years of experience in the medical device industry, primarily in
 the areas of regulatory/clinical affairs, compliance, quality systems,
 intellectual property, business development, litigation and general legal
 affairs. He brings experience from the law firm of Howard and Howard, the
 Surgical Group of the Stryker Corporation, and most recently Zassi Medical
 Evolutions where he served as the Vice President of Legal and Regulatory
 Affairs.
 
     "Chad brings extensive domain-specific knowledge and industry
 experience to our company," said Mr. Patrick Daly, President and CEO of
 Cohera Medical. "In addition to his regulatory expertise, he has published
 articles in Food and Drug Law Institute publications and has held
 board-level positions with Medical Device Associations. We are fortunate to
 have him as a member of our growing team."
 
     Mr. Coberly holds a J.D. from Michigan State University and a
 bachelor's degree in biomedical engineering from Tulane University. He also
 has completed MBA studies at Boston University. He is admitted to practice
 before the U.S. Patent and Trademark Office and is a member of the Michigan
 Bar.
 
     Cohera has also formalized its Clinical Advisory Board, which includes
 the following world renowned surgeons and scientists:
 
 

     -- Peter Rubin, MD is the Founder and Director of the Life After Weight
        Loss surgical body contouring program at the University of Pittsburgh,
        and author of "Aesthetic Plastic Surgery After Massive Weight Loss." He
        is the recipient of the Presidential Early Career Award for Scientists
        and Engineers, the highest honor bestowed upon young scientists by the
        United States government.
 
     -- Russell F. Warren, MD is the Surgeon-in-Chief Emeritus of the Hospital
        for Special Surgery (HSS) in Manhattan and Professor of Orthopedics at
        the Weill Medical College of Cornell University. He is currently the
        Team Physician for the New York Giants.
 
     -- Richard M. Green, MD, FACS is currently chairman, Department of
        Surgery, at Lenox Hill Hospital, in New York City. In 2005, he also
        became co-director, Division of Peripheral and Vascular Intervention at
        Lenox Hill Hospital.
 
     -- Michael Buckley, MD is co-founder of Cohera Medical and co-inventor of
        the company's core technology. He is an oral and maxillofacial surgeon
        in private practice. Dr. Buckley serves as the national Treasurer of
        the American Cleft Palate-Craniofacial Association.
     "Cohera has attracted quite a prestigious group of advisors to provide
 expert feedback on our efforts in new product development," said Mr. Daly.
 "We look forward to working with them to create products that will continue
 to revolutionize the practice of surgery in all disciplines."
 
     About Cohera Medical, Inc.
 
     Cohera Medical, Inc. is developing a revolutionary line of wound
 management products and surgical adhesives. Our products are based on a
 unique chemical design that is purely synthetic, easy to use, biocompatible
 and fully resorbable. Our lead product in development, TissuGlu(TM) Wound
 Management System, is a sprayable bonding agent for plastic surgery
 procedures. TissuGlu(TM) adheres flaps of tissue after surgical procedures,
 eliminating the spaces where fluid accumulates and reducing wound drainage.
 Pre-clinical testing has shown that TissuGlu(TM) virtually eliminates
 seroma formation, one of the most common complications of abdominoplasty
 procedures. Cohera is also developing additional surgical adhesives
 targeting mesh fixation and small bone fixation, which will fill similar
 market needs in both orthopedics and general surgery. TissuGlu(TM) and the
 other Cohera products have not yet been approved for medical use by the
 Food and Drug Administration (FDA) in the US or by any other country's
 regulatory authority.
 
 
 

SOURCE Cohera Medical, Inc.